THE USE OF A TRIPLE DETECTION SYSTEM (UV, ELSD, MS) FOR PHARMACEUTICAL DEGRADATION STUDIES

Significance of the Topic

Forced degradation testing and impurity profiling are critical to ensure the safety, efficacy, and regulatory compliance of pharmaceutical products. Combining UV, evaporative light scattering, and mass spectrometric detection provides comprehensive analytical coverage for compounds with diverse chemical properties.

Study Objectives and Overview

This work evaluates a triple detection system for forced acid degradation of the antidiabetic drug glimepiride. Goals include:

• Determining relative response factors (RRF) for related impurities using dual approaches
• Assessing mass balance accuracy over a 7-day acid hydrolysis study
• Verifying peak purity through orthogonal detection modes

Methodology and Instrumentation

Glimepiride and USP reference impurities B and C were subjected to 0.1 M HCl at 40 °C for up to 7 days. Samples were analyzed by reversed-phase UPLC under isocratic 60%A:40%B (0.1% formic acid in water/ACN) on a BEH C18 column (1.7 μm, 2.1×50 mm) at 30 °C. The flow was split post-PDA to an ELSD and QDa mass detector with make-up solvent (0.1% formic acid in methanol). Instrument details:

• ACQUITY UPLC H-Class with PDA detector (210–400 nm, 228 nm)
• ACQUITY ELSD (25 psi gas, 55 °C, cooling mode)
• ACQUITY QDa MS (100–600 Da, ESI+, cone 5 V, capillary 1.4 kV)

Main Results and Discussion

Calibration showed linear UV responses for glimepiride (1–250 µg/mL) and impurities (1–50 µg/mL), while ELSD exhibited a logarithmic response. RRF values calculated via slope ratios and UV peak area vs. log ELSD area were consistent and within acceptance criteria for ELSD-based methods. Peak purity assessment combining UV chromatograms, total ion chromatograms, and extracted ion chromatograms confirmed absence of co-elutions. Mass balance recoveries remained within ±2% over the degradation time course.

Benefits and Practical Applications

The triple detection approach enables:

• Reliable quantification of non-UV-active or poorly chromophoric impurities via ELSD and MS
• Cross-validation of quantitation through orthogonal detectors
• Accurate mass balance determination for forced degradation protocols
• Enhanced peak purity verification to support regulatory submissions

Future Trends and Possibilities

Advances may include integration of multi-dimensional chromatography with high-resolution MS, automated RRF computation in software platforms, and AI-driven peak deconvolution. These innovations will further streamline impurity profiling and stability testing in pharmaceutical development.

Conclusion

A combined UV-ELSD-MS detection system provides robust impurity quantitation, comprehensive peak purity assessment, and accurate mass balance in forced degradation studies, supporting rigorous pharmaceutical quality control.

References

1. Chapter <621> CHROMATOGRAPHY. United States Pharmacopeia and National Formulary (USP 37-NF 32). Baltimore, MD: United Book Press; 2014:6376-85.
2. Mark AN, Andreas K, Patrick JJ. Role of Mass Balance in Pharmaceutical Stress Testing. CRC Press; 2011:233-53.
3. Bansal G, Singh M, Jindal KC, Singh S. LC–UV–PDA and LC–MS Studies to Characterize Degradation Products of Glimepiride. J Pharm Biomed Anal. 2008;48:788-95.